Cephalon Doesn't Have the Right Medicine

by Jon Lewis  
Email This   Print Page  Tweet This Tweet This

Free Trading Guides

Cephalon (CEPH) is a drug manufacturer that is dwarfed by such competitors as Johnson & Johnson (JNJ) and GlaxoSmithKline (GSK).

Being smaller (if you want to call a $4 billion market cap "small") is not necessarily a bad thing, of course. But CEPH has some high expectations to fill, which could make it vulnerable to a so-so earnings report. The company is scheduled to report on Aug. 4.

CEPH usually beats the consensus earnings forecast, but that's not always a good thing for the stock.

The company beat estimates the past two quarters, but the stock sank nearly 6% and 14% in the two weeks following those reports.

On the charts, the stock has enjoyed a nice 11% run-up during the past week. This jump pulled the shares above their 20-day and 50-day moving averages. But now the 100-day looms overhead. The last time the stock saw the top side of this trendline was in February.

In addition, the $60 level could be problematic. This is the site of the bottom of the stock's downward gap in May and the March lows. The shares are also flirting with being overbought, which means it could be time to take a breather.

ceph

Sentiment toward CEPH is definitely tilted toward the optimistic side of the ledger, especially among analysts.

The Street clearly loves the stock, as 14 of 19 brokerages rate the shares a "strong buy," with the remaining five being "holds." That doesn't leave much room for upgrades.

Options traders are showing their preference for the shares, as the put/call ratio has been declining throughout July. And short interest is sitting among its lowest readings of the past two years.

CEPH could always issue a blowout earnings and outlook report. When that happens, any stock will go up, no matter what the technical and sentiment backdrop might be. But the odds of such a report from CEPH are slim. And that's what the stock appears to need to keep its brief rally intact. So consider buying puts on CEPH ahead of earnings.


This market is packed with opportunities to make big money … if you know where to look. Find the hidden money-doublers in today's stock market. Learn more in your FREE Options Report.

More By This Expert

Put Your Money Where Your Mouth Is

Despite the economic slowdown, consumers continue to purchase peanut butter, jelly and all other J.M. Smucker (SJM) products, and the stock may see a big move after earnings next week.

Dell May Take the Street by Surprise … Again

Dell (DELL) has some good things going for it heading into earnings that could make it a great candidate for a pre-earnings call play.

'CAT' About to be Let Out of the Bag

Heading into earnings, the indicators point to Caterpillar (CAT) breaking above its September high. So look at a bullish trade before the company reports.

Will HAL Bust Through the September Highs?

Skepticism in Halliburton (HAL) may be on the verge of unwinding into buying pressure, which could be what the stock needs to break out to new highs.

Breakout in INFY Almost a Sure Thing

Infosys Technologies (INFY) reports earnings next week, and that could very well be the key to a breakout in the stock.

Options Broker Center

Compare Brokers